Recent research has suggested that the antimalarial drug HCQS 200 (HCQ) may reduce the efficacy of anti-PD-1 cancer immunotherapy, a promising new approach to treating certain forms of cancer. This has raised serious questions about the role of HCQ in cancer treatment and the potential implications for patients. In this blog post, we will discuss the findings of the research and provide...